Merck KGaA announced that it has submitted an application to the European Medicines Agency (EMEA) to broaden the use of the targeted cancer therapy, Erbitux (cetuximab), to include first-line therapy for the treatment of metastatic colorectal cancer (mCRC). [click link for full article]
From: www.medicalnewstoday.com
Merck Applies To Extend Use Of Erbitux For 1st-Line Colorectal Cancer
Posted by Ruslan Abuzant at 3:09 AM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment